Pharmacology of platelet-affecting drugs.
D000818:Animals; D001095:Arachidonic Acids / Q000037:antagonists & inhibitors; D001161:Arteriosclerosis / Q000150:complications; D001241:Aspirin / Q000494:pharmacology; D001792:Blood Platelets / Q000187:drug effects*; D000242:Cyclic AMP / Q000097:blood; D004305:Dose-Response Relationship, Drug; D005260:Female; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D007213:Indomethacin / Q000494:pharmacology; D008297:Male; D010215:Papio; D010740:Phospholipases / Q000037:antagonists & inhibitors; D010973:Platelet Adhesiveness / Q000187:drug effects; D010979:Platelet Function Tests; D011817:Rabbits; D013442:Sulfinpyrazone / Q000494:pharmacology; D013917:Thrombin / Q000037:antagonists & inhibitors; D013923:Thromboembolism / Q000097:blood; D013927:Thrombosis / Q000097:blood; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors; D014661:Vasoconstriction / Q000187:drug effects; D014693:Ventricular Fibrillation / Q000517:prevention & control
D001095:Arachidonic Acids; D006493:Heparin; D000242:Cyclic AMP; D010740:Phospholipases; D013917:Thrombin; D013930:Thromboxane-A Synthase; D001241:Aspirin; D013442:Sulfinpyrazone; D007213:Indomethacin